Outcomes4Me Inc., the developer of a personalized and evidence-based cancer navigation platform, and the National Comprehensive Cancer Network announced that Outcomes4Me has newly incorporated...
Onco360, the nation’s leading independent Specialty Pharmacy, has been selected by Mirati Therapeutics to be a specialty pharmacy partner for KRAZATI, which is an...
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination with platinum-based chemotherapy...
RedCloud Bio (the "Company"), an innovative biotech company integrating structural pharmacology and computational approaches to advance small molecule drug discovery and development, announced completion...
